Department of Medicine, Huddinge, Karolinska Institutet, Stockholm, Sweden.
Department of Medicine, Huddinge, Karolinska Institutet, Stockholm, Sweden; Division of Hepatology, Department of Upper GI, Karolinska University Hospital, Stockholm, Sweden; Clinical Epidemiology Unit, Department of Medicine, Stockholm, Karolinska Institutet, Stockholm, Sweden.
Clin Gastroenterol Hepatol. 2023 May;21(5):1359-1361.e2. doi: 10.1016/j.cgh.2022.03.020. Epub 2022 Mar 24.
Patients with nonalcoholic fatty liver disease (NAFLD) often have hyperlipidemia and are at a higher risk of cardiovascular disease (CVD). As first-line lipid-lowering drugs, statins are widely used for primary and secondary CVD prevention. However, there have been concerns about statins underprescription for patients with NAFLD because of fear of hepatoxicity. We aimed to describe and compare the pattern of statins use before and after CVD events in patients with NAFLD with the general population.
非酒精性脂肪性肝病（NAFLD）患者常伴有血脂异常，心血管疾病（CVD）风险较高。他汀类药物作为一线降脂药物，广泛用于 CVD 的一级和二级预防。然而，由于担心他汀类药物的肝毒性，NAFLD 患者的他汀类药物处方不足。本研究旨在描述和比较 NAFLD 患者 CVD 事件前后与普通人群他汀类药物使用模式。
